SPCC417.16 Antibody

What is SPCC417.16 Antibody and what organism does it target?

SPCC417.16 Antibody (product code CSB-PA520561XA01SXV) is a research-grade antibody developed against a specific protein from Schizosaccharomyces pombe, commonly known as fission yeast . The antibody targets the SPCC417.16 protein, which is identified in the UniProt database with accession number G2TRT6 . This antibody was generated using recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843) SPCC417.1 as the immunogen . Fission yeast serves as an important model organism in molecular and cellular biology research, particularly for studying cell cycle regulation, DNA damage responses, and other fundamental cellular processes. The antibody provides researchers with a tool to detect and study the SPCC417.16 protein, which may have important functions in yeast cellular processes that could have implications for understanding conserved mechanisms in eukaryotic cells.

How does SPCC417.16 Antibody compare to other yeast protein antibodies in terms of specificity and cross-reactivity?

While specific cross-reactivity data for SPCC417.16 Antibody is limited in the provided information, researchers should anticipate potential reactivity patterns similar to those observed with other monoclonal antibodies targeting yeast proteins. In general, antibodies developed against specific yeast proteins exhibit varying degrees of cross-reactivity with homologous proteins from related species. The specificity of SPCC417.16 Antibody would need to be empirically determined through careful validation experiments comparing reactivity against the target protein versus potential homologs in other yeasts or fungal species. When designing experiments, researchers should consider performing validation tests similar to those used with other monoclonal antibodies, such as the rhinovirus antibody which exhibits specific reactivity patterns against capsid proteins VP2 and its precursors . Cross-reactivity assessment is particularly important for evolutionary studies or when working with multiple yeast species, as it can provide insights into protein conservation and structural similarities across evolutionarily related organisms.

What is the optimal storage condition for maintaining SPCC417.16 Antibody activity long-term?

For optimal preservation of SPCC417.16 Antibody activity, store the antibody at -20°C or -80°C upon receipt, and critically, avoid repeated freeze-thaw cycles that can significantly degrade antibody performance . This storage recommendation aligns with standard practices for preserving antibody functionality, as repeated temperature fluctuations can lead to protein denaturation and loss of epitope recognition capability. For working solutions, researchers should consider aliquoting the stock antibody into smaller volumes suitable for individual experiments, adding cryoprotectants such as glycerol (typically 30-50%) for storage solutions intended for -20°C, and maintaining sterile conditions during handling to prevent microbial contamination. Additionally, researchers should implement a quality control system to track antibody performance over time, potentially including regular validation experiments with positive controls to ensure consistent reactivity throughout the antibody's usable lifespan. Proper storage documentation, including freeze-thaw cycles and performance notes, will help maintain experimental reproducibility across long-term research projects.

What are the recommended protocols for using SPCC417.16 Antibody in immunoblotting experiments with yeast lysates?

When employing SPCC417.16 Antibody for immunoblotting experiments with yeast lysates, researchers should implement a protocol optimized for yeast proteins, which typically have unique extraction challenges. Begin by preparing yeast lysates using either mechanical disruption (glass beads) or enzymatic methods (zymolyase treatment) followed by detergent-based lysis in the presence of protease inhibitors to prevent degradation of the target protein. For SDS-PAGE separation, load 20-50 μg of total protein per lane on 10-12% gels to achieve optimal resolution of the target protein. After transfer to nitrocellulose or PVDF membranes, block with 5% non-fat milk or 3-5% BSA in TBST for 1 hour at room temperature. Drawing from protocols used with other antibodies, such as the rhinovirus antibody which is typically used at 2-5 μg/ml for immunoblotting , researchers might start with SPCC417.16 Antibody at a similar concentration range (1:500 to 1:2000 dilution) in blocking buffer and incubate overnight at 4°C. After washing with TBST, apply an appropriate HRP-conjugated secondary antibody and develop using enhanced chemiluminescence. Critical controls should include wild-type yeast lysate, a knockout strain lacking the target protein if available, and potentially a recombinant version of the target protein as a positive control.

How should researchers approach the optimization of SPCC417.16 Antibody for immunofluorescence microscopy in fission yeast cells?

For immunofluorescence microscopy using SPCC417.16 Antibody in fission yeast cells, researchers should develop an optimization strategy addressing the unique cell wall constraints of yeast while preserving epitope integrity. Begin with cell fixation optimization, testing both formaldehyde (3-4%, 30 minutes) and methanol (-20°C, 6 minutes) fixation methods in parallel to determine which best preserves the epitope recognized by SPCC417.16 Antibody. Cell wall digestion is critical for antibody accessibility—evaluate different zymolyase concentrations (0.5-2 mg/ml) and treatment durations (15-45 minutes at 37°C) to achieve optimal permeabilization without compromising cellular structures. When establishing antibody dilutions, start with a broader range (1:50 to 1:500) than typically used for immunoblotting, as immunofluorescence often requires higher antibody concentrations. Incorporate appropriate controls including a secondary-only control to assess background fluorescence, wild-type cells as positive controls, and if available, cells with the target gene deleted as negative controls. Drawing from immunohistochemistry approaches used with other antibodies like the rhinovirus antibody (used at 1-10 μg/ml) , researchers should systematically adjust incubation conditions (temperature, duration, antibody concentration) to achieve optimal signal-to-noise ratios while confirming specificity through colocalization with known markers or protein tags where applicable.

What strategies can be employed to validate SPCC417.16 Antibody specificity in chromatin immunoprecipitation (ChIP) experiments?

Validating SPCC417.16 Antibody specificity for chromatin immunoprecipitation experiments requires a multi-faceted approach to ensure reliable and reproducible results. First, researchers should perform preliminary Western blot analyses using nuclear extracts to confirm the antibody recognizes the target protein at the expected molecular weight in the nuclear fraction. For ChIP optimization, begin with a crosslinking titration experiment testing formaldehyde concentrations (0.75-1.5%) and incubation times (5-20 minutes) to determine optimal DNA-protein crosslinking conditions for the target protein. When establishing antibody amounts for immunoprecipitation, test a range (2-10 μg per reaction) to determine the minimal amount needed for efficient pull-down while avoiding non-specific binding. Critical validation controls should include: (1) input samples representing the starting chromatin material, (2) IgG control to establish background signals, (3) a positive control using antibody against a well-characterized yeast protein like histone H3, and (4) ideally, a strain with the target gene deleted or containing an epitope-tagged version that can be immunoprecipitated with a different antibody for comparison. Drawing from approaches used to identify epitope-specific antibodies in other contexts , researchers should assess enrichment at predicted binding sites using qPCR with primers targeting regions where the protein is expected to bind, alongside control regions where binding is not anticipated, calculating fold-enrichment relative to both input and negative control regions.

What are common issues encountered when using SPCC417.16 Antibody and how can researchers address them?

Researchers working with SPCC417.16 Antibody may encounter several technical challenges that can be systematically addressed with appropriate troubleshooting strategies. High background signal in immunoblotting or immunofluorescence experiments often results from insufficient blocking or excessive antibody concentration, which can be resolved by increasing blocking time (2-3 hours instead of 1 hour), using alternative blocking agents (switch between milk, BSA, or commercial blocking buffers), and titrating the antibody to lower concentrations. Weak or absent signals may indicate epitope masking or denaturation, requiring researchers to evaluate alternative fixation methods, adjust antigen retrieval protocols, or test different buffer compositions that might better preserve the epitope structure. Cross-reactivity with non-target proteins can complicate data interpretation and may necessitate additional pre-absorption steps with yeast lysates lacking the target protein or affinity purification of the antibody against the immunogen. Similar to strategies employed with other monoclonal antibodies used in virus detection , researchers should implement both positive and negative controls in each experiment, including wild-type samples alongside gene deletion strains if available. Additionally, batch-to-batch variation in antibody performance should be monitored through consistent validation experiments with standard samples, creating an internal reference dataset to ensure experimental reproducibility across different antibody lots and research projects.

How can researchers optimize antigen retrieval protocols for detecting SPCC417.16 protein in fixed yeast samples?

Optimizing antigen retrieval protocols for detecting SPCC417.16 protein in fixed yeast samples requires a systematic approach addressing the unique cell wall and protein crosslinking challenges encountered with yeast specimens. Researchers should begin by evaluating both heat-mediated and enzymatic retrieval methods in parallel experiments. For heat-mediated retrieval, test a range of buffer conditions including citrate buffer (pH 6.0), Tris-EDTA (pH 9.0), and glycine-HCl (pH 3.5) with heating variables of 90-100°C for 10-30 minutes or using microwave protocols with 2-3 cycles of 5 minutes each. Enzymatic retrieval alternatives should include proteinase K (5-20 μg/ml, 5-15 minutes at 37°C) and trypsin (0.05-0.1%, 5-10 minutes at 37°C) digestion trials. The rigid yeast cell wall presents a particular challenge, necessitating consideration of pre-treatment with cell wall digesting enzymes such as zymolyase (0.5-2 mg/ml), lysing enzymes (1-5 mg/ml), or glucanases (50-200 units/ml) prior to standard antigen retrieval. When optimizing these protocols, researchers should process multiple slide sections or sample aliquots in parallel, testing each variable while maintaining others constant, and quantifying signal intensity using standardized imaging parameters. Drawing from methodologies applied with other specialized antibodies , researchers should maintain detailed records of protocol variations and results, potentially developing a custom combinatorial approach that begins with gentle cell wall digestion followed by optimized heat or enzymatic epitope retrieval tailored specifically for the SPCC417.16 protein's structural characteristics.

What strategies can be employed to enhance signal detection when using SPCC417.16 Antibody in low-expression contexts?

Enhancing signal detection for SPCC417.16 Antibody in low-expression contexts requires implementing advanced signal amplification techniques while maintaining specificity. Researchers should first consider enriching the target protein through subcellular fractionation protocols specific to the protein's expected localization, concentrating the relevant cellular fraction prior to analysis. For immunoblotting applications, switching from conventional HRP-based detection to more sensitive chemiluminescent substrates (Super Signal West Femto or similar high-sensitivity reagents) can significantly improve detection limits, while longer exposure times with cooled CCD cameras may capture weaker signals that film-based methods might miss. In microscopy applications, implement signal amplification systems such as tyramide signal amplification (TSA), which can enhance fluorescence signals 10-100 fold over conventional secondary antibody detection. Alternative detection approaches include employing biotinylated secondary antibodies followed by streptavidin-conjugated fluorophores or enzymes, creating multi-layer amplification systems. Drawing from methodologies used with other specialized antibodies , researchers working with potentially low-abundance SPCC417.16 protein should also optimize sample preparation to reduce potential degradation through more comprehensive protease inhibitor cocktails, lower processing temperatures, and shorter procedural timeframes. Additionally, consider enhancing protein expression experimentally prior to detection, either through physiological induction of the native protein (if regulatory mechanisms are known) or through genetic approaches that place the gene under control of stronger promoters while maintaining physiological relevance.

How can SPCC417.16 Antibody be utilized in co-immunoprecipitation studies to identify novel protein interaction partners?

SPCC417.16 Antibody can be strategically employed in co-immunoprecipitation studies to uncover novel protein interactions within the fission yeast interactome through a carefully designed experimental approach. Researchers should begin by optimizing lysis conditions that preserve native protein interactions, testing multiple buffer systems (HEPES, Tris, or phosphate-based) with varying salt concentrations (100-300 mM), different detergents (NP-40, Triton X-100, or digitonin at 0.1-1%), and appropriate protease/phosphatase inhibitor combinations. For the immunoprecipitation procedure, compare direct antibody immobilization approaches (covalently coupling SPCC417.16 Antibody to activated beads) versus indirect methods (protein A/G beads added after antibody-lysate incubation) to determine which maximizes pull-down efficiency while minimizing background. Pre-clearing lysates with isotype-matched control antibodies and corresponding beads can significantly reduce non-specific binding. Critical controls should include parallel immunoprecipitations with non-specific IgG, a known target protein antibody as positive control, and ideally, samples from strains with SPCC417.16 deleted. Drawing from methodologies used in other epitope-specific antibody studies , researchers should consider both stringent and mild washing conditions in parallel experiments, as some biologically relevant interactions may be transient or sensitive to high salt or detergent concentrations. For interaction partner identification, mass spectrometry analysis of co-immunoprecipitated proteins offers the most comprehensive approach, with candidates prioritized by peptide abundance, reproducibility across replicates, and absence in control samples, followed by reciprocal co-immunoprecipitation validation of high-confidence interaction candidates.

What approaches should researchers consider when adapting SPCC417.16 Antibody for quantitative proteomic analyses?

When adapting SPCC417.16 Antibody for quantitative proteomic analyses, researchers should implement a multi-faceted strategy that addresses both technical limitations and biological variability. Begin by validating the antibody's linearity of response across a concentration gradient of purified target protein or whole cell lysates from strains with known expression levels of SPCC417.16 protein, establishing a quantifiable dynamic range for subsequent experiments. For immunoblot-based quantitation, develop standard curves using recombinant SPCC417.16 protein at known concentrations, ensuring analysis occurs within the linear detection range of both the antibody and detection system. Consider implementing multiplexed approaches through antibody combinations targeting both SPCC417.16 and established loading control proteins optimized for simultaneous detection with distinct fluorophores. For mass spectrometry-based quantitation following immunoprecipitation, evaluate both label-free approaches and isotope labeling techniques (SILAC, TMT, or iTRAQ) to determine which provides the most reproducible quantitation with SPCC417.16 Antibody. Critical considerations include optimizing immunoprecipitation efficiency through antibody titration experiments and determining the minimum amount of antibody needed for consistent pull-down across samples. Drawing from approaches used with other specialized antibodies , researchers should implement careful experimental design with biological and technical replicates, appropriate normalization strategies, and statistical analysis methods suitable for the specific quantitation approach. Additionally, researchers should validate quantitative findings through orthogonal methods such as comparing immunoblot results with targeted mass spectrometry or fluorescence-based assays to ensure robust and reproducible quantitation of SPCC417.16 protein across experimental conditions.

How can structural biology approaches be combined with SPCC417.16 Antibody to elucidate protein function?

Integrating structural biology approaches with SPCC417.16 Antibody-based studies can provide profound insights into protein function through a complementary experimental strategy. Researchers can utilize SPCC417.16 Antibody for epitope mapping via hydrogen-deuterium exchange mass spectrometry (HDX-MS) or limited proteolysis followed by mass spectrometry, identifying the specific binding region and potentially revealing functionally important domains of the target protein. The antibody itself can serve as a crystallization chaperone in X-ray crystallography studies, where antibody-protein complexes often crystallize more readily than the protein alone, potentially stabilizing flexible regions and facilitating structure determination. For cryo-electron microscopy (cryo-EM) applications, SPCC417.16 Antibody can function as a molecular marker, helping to identify protein orientation and providing phase information for image reconstruction. Drawing from approaches used with other specialized monoclonal antibodies , researchers should consider producing F(ab) fragments from SPCC417.16 Antibody through controlled protease digestion, removing the more flexible Fc region while retaining antigen recognition properties, which can improve structural studies by reducing conformational heterogeneity. Additionally, the antibody can be employed in single-molecule fluorescence resonance energy transfer (smFRET) experiments, where fluorescently labeled antibody binding can reveal conformational changes in the target protein under various conditions. This multi-technique approach combining antibody-based recognition with advanced structural methods creates a powerful platform for elucidating both static structural features and dynamic conformational changes of SPCC417.16 protein, potentially revealing mechanisms underlying its cellular functions in fission yeast.

What are the key considerations for researchers designing long-term studies with SPCC417.16 Antibody?

Researchers planning long-term studies with SPCC417.16 Antibody should implement comprehensive strategies addressing both technical consistency and experimental design robustness. Establish antibody validation benchmarks at project initiation, including specificity testing via Western blot, immunoprecipitation efficiency assessment, and if possible, validation in knockout or knockdown strains to serve as reference standards throughout the project duration. For reagent consistency, consider purchasing sufficient antibody quantities from a single manufacturing lot at the outset, preparing master aliquots stored at -80°C with minimal freeze-thaw cycles, and implementing regular quality control testing against established benchmarks to monitor potential performance degradation over time. Experimental designs should incorporate appropriate positive and negative controls in every experiment, alongside internal reference samples that remain consistent throughout the study period, enabling cross-experiment normalization and trend analysis. Long-term projects benefit significantly from detailed protocol documentation, including antibody dilutions, incubation conditions, detection methods, and even minor technical adjustments, ensuring procedural consistency even with personnel changes. Drawing from approaches used with other specialized antibodies in longitudinal studies , researchers should consider developing quantitative metrics for antibody performance, potentially including signal-to-noise ratios, detection limits, and reproducibility measurements, tracking these metrics throughout the project lifespan. Additionally, maintain awareness of potential biological variability in the target protein's expression or modification under different experimental conditions, distinguishing technical variation from genuine biological changes through appropriate experimental designs incorporating biological replicates and time-course analyses where applicable.

How might future developments in antibody engineering impact research applications of SPCC417.16 Antibody?

Future developments in antibody engineering will likely transform research applications for SPCC417.16 Antibody by enhancing its utility, specificity, and functionality across multiple experimental platforms. Emerging recombinant antibody technologies may enable the production of smaller antibody formats such as single-chain variable fragments (scFv) or nanobodies derived from SPCC417.16 Antibody's binding domains, offering improved tissue penetration, reduced steric hindrance, and enhanced epitope accessibility in complex yeast cellular structures. Site-specific conjugation methods are evolving to replace random chemical labeling, potentially allowing precise attachment of fluorophores, enzymes, or affinity tags to SPCC417.16 Antibody without compromising binding affinity or introducing functional heterogeneity. Computational approaches to antibody engineering, including in silico humanization and affinity maturation, might be applied to optimize SPCC417.16 Antibody properties, potentially increasing specificity or broadening cross-reactivity to homologous proteins in related species as needed for comparative studies. Drawing from approaches seen with other advanced antibody systems , researchers might eventually benefit from bifunctional versions of SPCC417.16 Antibody capable of simultaneously binding the target protein and recruiting additional molecules (such as fluorescent proteins, degradation machinery, or enzymatic reporters) through genetically fused secondary binding domains. Additionally, the integration of SPCC417.16 Antibody with emerging technologies such as proximity labeling, where antibody binding triggers localized protein tagging, could facilitate more comprehensive mapping of protein interaction networks in their native cellular context, providing unprecedented insights into SPCC417.16 protein's functional interactions within fission yeast cellular processes.